PaTHway Phase 3 Trial Analysis

Active Vitamin D Dose (Mean +/- SE) by Visit 1.8 ратнішач TransCon PTH Placebo 1.6 1.4 Active 1.2 Vitamin D 1.0 Dose μg/day Mean (± SE) 0.8 0.6 0.4 0.2 0.0 0 4 8 12 16 20 24 28 Weeks TransCon PTH patients discontinued active vitamin D completely within four weeks 17 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. ascendis pharma TRIAL

View entire presentation